On May 7, 2018, Impax Laboratories, Inc. combined with Amneal Pharmaceuticals, Inc. (NYSE:AMRX) to create a dynamic company powered by a robust U.S. generics business and growing branded franchise. Today, we are working to integrate our business into the new Amneal and are excited about our future as one company.
Amneal + Impax R&D
Our R&D strategy is led by a deeply accomplished in-house development team and supplemented by creative product development partnerships with external stakeholders. The focus of our R&D strategies is ensuring the ongoing development of important and value-generating products within our Generic and Specialty Pharma divisions.